AFP、AFU及TSGF联合检测对原发性肝癌的诊断价值  

Clinical Value of Combined Determination of Serum AFP,AFU and TSGF Levels in Patients with Primary Hepatic Cancer

作　　者：涂少华[1] 沈江帆[1] 朱敏[1] 方云华[1] 杨琦[1] 

机构地区：[1]上海市普陀区中心医院核医学科,上海200062

出　　处：《标记免疫分析与临床》2007年第3期129-130,134,共3页Labeled Immunoassays and Clinical Medicine

摘　　要：探讨血清AFP、AFU及TSGF联合检测对原发性肝癌(PHC)的诊断价值。对PHC患者72例、良性肝病患者60例及对照组56例应用微粒子酶免疫法检测AFP;生物方法检测AFU和TSGF。结果表明:在PHC患者中单一肿瘤标志物AFP检测阳性率为69.4%,AFU为55.6%,TSGF为61.1%;二个肿瘤标志物(AFP、AFU)和三个肿瘤标志物(AFP、AFU及TSGF)联合检测阳性率则显著提高,分别为93.0%和95.8%,与单一AFP阳性率相比有显著性差异(P<0.01)。AFP、AFU及TSGF联合检测在PHC的诊断中有互补性,并能提高检出率,具有临床诊断意义。To explore the clinical value of combined test of serum AFP, AFU and TSGF levels in the diagnosis of primary hepatic cancer（PHC）, the levels of serum AFP, AFU and TSGF in 72 patients with PHC, 60 patients with benign liver disease and 56 normal controls were determined by micro-particle enzyme immunoassay and biochemistry method. The results showed that the positive rate of the serum AFP, AFU and TSGF in patients with PHC were 69.4%, 55. 6% and 61. 1% separately. The positive rate of the combined test of two tumor markers （AFP and AFU） and three tumor markers （AFP, AFU and TSGF） was 93.0% and 95.8% in patients with PHC respectively. The diagnostic positive ra,te of combined test of three tumor markers for PHC were significantly higher than that of single tumor marker test （P〈0. 01）. The combined determination of AFP, AFU and TSGF is complementary and meaningful in the diagnosis of PHC.

关 键 词：甲胎蛋白 Α-L-岩藻糖苷酶 恶性肿瘤特异性生长因子 原发性肝癌 联合检测 

分 类 号：R735.7[医药卫生—肿瘤]